0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Cytokines > IL-22 > IL2-H8247

Biotinylated Human IL-22 Protein, His,Avitag™

  • Synonym
    IL-22,IL-TIF,ZCYTO18
  • Source
    Biotinylated Human IL-22, His,Avitag™ (IL2-H8247) is expressed from human 293 cells (HEK293). It contains AA Ala 34 - Ile 179 (Accession # Q9GZX6-1).
    Predicted N-terminus: His
  • Molecular Characterization
    Online(Ala 34 - Ile 179) Q9GZX6-1

    This protein carries a polyhistidine tag at the N-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 20.3 kDa. The protein migrates as 25-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Biotinylation
    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Biotinylated Human IL-22, His,Avitag™ (Cat. No. IL2-H8247) SDS-PAGE gel

Biotinylated Human IL-22, His,Avitag™ on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

Bioactivity-ELISA
Biotinylated Human IL-22, His,Avitag™Biotinylated Human IL-22, His,Avitag™ (Cat. No. IL2-H8247) ELISA bioactivity

Immobilized Biotinylated Human IL-22, His,Avitag (Cat. No. IL2-H8247) at 1 μg/mL (100 μL/well)on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate. can bind Human IL-22 Antibody with a linear range of 0.1-4 ng/mL (QC tested).

Biotinylated Human IL-22, His,Avitag™Biotinylated Human IL-22, His,Avitag™ (Cat. No. IL2-H8247) ELISA bioactivity

Immobilized Human IL-22 Antibody at 1 μg/mL (100 μL/well) can bind Biotinylated Human IL-22, His,Avitag (Cat. No. IL2-H8247) with a linear range of 1-31 ng/mL (Routinely tested).

  • Background
    Interleukin-22 (IL22) is also known as cytokine Zcyto18, IL-10-related T-cell-derived-inducible factor (IL-TIF), which is belongs to the IL-10 family or IL-10 superfamily (including IL-19, IL-20, IL-24, and IL-26), a class of potent mediators of cellular inflammatory responses. IL-22 is produced by activated DC and T cells and initiates innate immune responses against bacterial pathogens especially in epithelial cells such as respiratory and gut epithelial cells. IL-22 biological activity is initiated by binding to a cell-surface complex composed of IL-22R1 and IL-10R2 receptor chains and further regulated by interactions with a soluble binding protein IL-22BP. IL-22 also promotes hepatocyte survival in the liver and epithelial cells in the lung and gut similar to IL-10.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $350.00

Price(USD) : $1380.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:1 Details
  • Latest Research Phase:Phase 2 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop